BACKGROUND: G protein-coupled inwardly rectifying potassium (K(IR) 3) channels are important proteins that regulate numerous physiological processes including excitatory responses in the CNS and the control of heart rate. Flavonoids have been shown to have significant health benefits and are a diverse source of compounds for identifying agents with novel mechanisms of action. EXPERIMENTAL APPROACH: The flavonoid glycoside, naringin, was evaluated on recombinant human K(IR) 3.1-3.4 and K(IR) 3.1-3.2 expressed in Xenopus oocytes using two-electrode voltage clamp methods. In addition, we evaluated the activity of naringin alone and in the presence of the K(IR) 3 channel blocker tertiapin-Q (0.5 nM, 1 nM and 3 nM) at recombinant K(IR) 3.1-3.4 channels. Site-directed mutagenesis was used to identify amino acids within the M1-M2 loop of the K(IR) 3.1(F137S) mutant channel important for naringin's activity. KEY RESULTS: Naringin (100 µM) had minimal effect on uninjected oocytes but activated K(IR) 3.1-3.4 and K(IR) 3.1-3.2 channels. The activation by naringin of K(IR) 3.1-3.4 channels was inhibited by tertiapin-Q in a competitive manner. An alanine-scan performed on the K(IR) 3.1(F137S) mutant channel, replacing one by one aromatic amino acids within the M1-M2 loop, identified tyrosines 148 and 150 to be significantly contributing to the affinity of naringin as these mutations reduced the activity of naringin by 20- and 40-fold respectively. CONCLUSIONS AND IMPLICATIONS: These results show that naringin is a direct activator of K(IR) 3 channels and that tertiapin-Q shares an overlapping binding site on the K(IR) 3.1-3.4. This is the first example of a ligand that activates K(IR) 3 channels by binding to the extracellular M1-M2 linker of the channel.
BACKGROUND: G protein-coupled inwardly rectifying potassium (K(IR) 3) channels are important proteins that regulate numerous physiological processes including excitatory responses in the CNS and the control of heart rate. Flavonoids have been shown to have significant health benefits and are a diverse source of compounds for identifying agents with novel mechanisms of action. EXPERIMENTAL APPROACH: The flavonoid glycoside, naringin, was evaluated on recombinant human K(IR) 3.1-3.4 and K(IR) 3.1-3.2 expressed in Xenopus oocytes using two-electrode voltage clamp methods. In addition, we evaluated the activity of naringin alone and in the presence of the K(IR) 3 channel blocker tertiapin-Q (0.5 nM, 1 nM and 3 nM) at recombinant K(IR) 3.1-3.4 channels. Site-directed mutagenesis was used to identify amino acids within the M1-M2 loop of the K(IR) 3.1(F137S) mutant channel important for naringin's activity. KEY RESULTS:Naringin (100 µM) had minimal effect on uninjected oocytes but activated K(IR) 3.1-3.4 and K(IR) 3.1-3.2 channels. The activation by naringin of K(IR) 3.1-3.4 channels was inhibited by tertiapin-Q in a competitive manner. An alanine-scan performed on the K(IR) 3.1(F137S) mutant channel, replacing one by one aromatic amino acids within the M1-M2 loop, identified tyrosines 148 and 150 to be significantly contributing to the affinity of naringin as these mutations reduced the activity of naringin by 20- and 40-fold respectively. CONCLUSIONS AND IMPLICATIONS: These results show that naringin is a direct activator of K(IR) 3 channels and that tertiapin-Q shares an overlapping binding site on the K(IR) 3.1-3.4. This is the first example of a ligand that activates K(IR) 3 channels by binding to the extracellular M1-M2 linker of the channel.
Authors: Sebastián P Fernández; Cristina Wasowski; Leonardo M Loscalzo; Renee E Granger; Graham A R Johnston; Alejandro C Paladini; Mariel Marder Journal: Eur J Pharmacol Date: 2006-04-06 Impact factor: 4.432
Authors: Flavia Carla Meotti; Ana Paula Luiz; Moacir Geraldo Pizzolatti; Cândida A L Kassuya; João B Calixto; Adair R S Santos Journal: J Pharmacol Exp Ther Date: 2005-10-31 Impact factor: 4.030
Authors: Kristian Kaufmann; Ian Romaine; Emily Days; Conrado Pascual; Adam Malik; Liya Yang; Bende Zou; Yu Du; Greg Sliwoski; Ryan D Morrison; Jerod Denton; Colleen M Niswender; J Scott Daniels; Gary A Sulikowski; Xinmin Simon Xie; Craig W Lindsley; C David Weaver Journal: ACS Chem Neurosci Date: 2013-06-13 Impact factor: 4.418
Authors: Wandong Wen; Wenjun Wu; Ian M Romaine; Kristian Kaufmann; Yu Du; Gary A Sulikowski; C David Weaver; Craig W Lindsley Journal: Bioorg Med Chem Lett Date: 2013-06-20 Impact factor: 2.823
Authors: Dinesh C Indurthi; Elena Pera; Hye-Lim Kim; Cindy Chu; Malcolm D McLeod; J Michael McIntosh; Nathan L Absalom; Mary Chebib Journal: Biochem Pharmacol Date: 2014-02-15 Impact factor: 5.858
Authors: Nicole Wydeven; Ezequiel Marron Fernandez de Velasco; Yu Du; Michael A Benneyworth; Matthew C Hearing; Rachel A Fischer; Mark John Thomas; C David Weaver; Kevin Wickman Journal: Proc Natl Acad Sci U S A Date: 2014-07-07 Impact factor: 11.205
Authors: Susan J Ramos-Hunter; Darren W Engers; Kristian Kaufmann; Yu Du; Craig W Lindsley; C David Weaver; Gary A Sulikowski Journal: Bioorg Med Chem Lett Date: 2013-07-18 Impact factor: 2.823